Aptuit LLC Names Dr. Maurizio Denaro as General Manager in Verona, Italy

 

Aptuit LLC Names Dr. Maurizio Denaro as General Manager in Verona, Italy


GREENWICH, Conn.July 22, 2013 /PRNewswire/ -- Aptuit has announced that Dr. Maurizio Denaro has assumed responsibilities as General Manager of The Aptuit Center for Discovery & Development in Verona, Italy, effective July 15, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )

Stuart Needleman, Aptuit's President and Chief Operating Officer, cited Dr. Denaro's global experience as a highly successful Research & Development executive. Mr. Needleman said, "We are delighted to have Maurizio on board, and I am pleased that he will be bringing us his expertise in the global life science industry. As the site's General Manager, Dr. Denaro will also become a member of our Executive Committee, applying his experience and insight to assist in the long-term strategic direction of Aptuit Verona. In every way, we are looking forward to the continued growth and success of our uniquely integrated outsourcing solution for discovery and development in Verona, optimistic that it will prosper under Maurizio's talented leadership."

Dr. Denaro's distinguished career has included corporate and R&D leadership roles at global life science companies in both Europeand the United States, including Bracco Imaging, where he was responsible for the ultrasound business unit, Marion Merrell Dow, OSI Pharmaceuticals, Amylin Pharmaceuticals and Hoechst Marion Roussel.

In accepting this position Dr. Denaro stated, "In only three years, Aptuit's drug discovery and development site in Verona has become a very valuable resource for life sciences companies around the world. It is my objective to maintain the steady progress that has been made to date while also initiating further growth through scientific excellence and a commitment to industry-leading service."

After earning a degree in Medicine from the University of Bologna, Italy, Dr. Denaro continued his post-doctoral studies in the United States at Stanford Medical School's Department of Genetics and as a Senior Researcher at the Wallenburg Laboratory, Uppsala UniversitySweden. He then became a Research Associate in Experimental Oncology at the Centro di Riferimento Oncologico inAviano, Italy. Dr. Denaro is credited with the filing of 19 patents and his findings have appeared in 59 publications.

For more information, please send an email to [email protected] or contact Maria Garvey, Delfino Marketing at 914-747-1400 or[email protected].

* * * *

Aptuit is a global pharmaceutical services company focusing on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide driven by a deep commitment to client service, quality and an unrivalled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. For more information about Aptuit, visit www.aptuit.com.

SOURCE Aptuit

 

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.